Effectiveness of generic sofosbuvir in the treatment of chronic hepatitis C virus infection in Saudi patients

References

1. 1.↵
   World Health Organization. The growing threats of hepatitis B and C in the Eastern Mediterranean Region: a call for action. [Udpated 2009; Accessed 2023 March 19] Available from: https://applications.emro.who.int/docs/EM_RC56_3_en.pdf
2. 2.↵
   1. Aljumah AA,
   2. Kuriry H,
   3. Faisal N,
   4. Alghamdi H

   . Clinicopathologic characteristics and outcomes of hepatocellular carcinoma associated with chronic hepatitis B versus hepatitis C infection. Ann Saudi Med 2018; 38: 358–365.

   OpenUrl
3. 3.↵
   1. Al MI,
   2. Abaalkhail FA,
   3. Bahili HA,
   4. Abdo AH,
   5. Elsiesy HA,
   6. Al MS, et al.

   Liver transplantation at KFSHRC: achievement and challenges. Ann Saudi Med 2014; 34: 103–106.

   OpenUrl
4. 4.↵
   AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. [Updated 2023: accessed 2023 May 20]. Available from: http://www.hcvguidelines.org
5. 5.↵
   1. Sofia MJ,
   2. Bao D,
   3. Chang W,
   4. Du J,
   5. Nagarathnam D,
   6. Rachakonda S, et al.

   Discovery of a β-d-2′-deoxy-2′-α-fluoro-2′-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 2010; 53: 7202–7218.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Gao M,
   2. Nettles RE,
   3. Belema M,
   4. Snyder LB,
   5. Nguyen VN,
   6. Fridell RA, et al.

   Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465: 96–100.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   1. Alghamdi AS,
   2. Alqutub A,
   3. Abaalkhail F,
   4. Sanai FM,
   5. Alghamdi H,
   6. Altraif I, et al.

   SASLT position statement on the direct-acting antiviral agents for the treatment of hepatitis C virus infection. Saudi J Gastroenterol 2015; 21: 60–63.

   OpenUrl
8. 8.↵
   1. Cui F,
   2. Blach S,
   3. Manzengo Mingiedi C,
   4. Gonzalez MA,
   5. Sabry Alaama A,
   6. Mozalevskis A, et al.

   Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol Hepatol 2023; 8: 332–342.

   OpenUrl
9. 9.↵
   1. Ward JW,
   2. Mermin JH

   . Simple, effective, but out of reach? public health implications of HCV drugs. N Engl J Med 2015; 3 73: 2678–2680.

   OpenUrl
10. 10.↵
    World Health Organization. WHO moves to improve access to lifesaving medicines for hepatitis C, drug-resistant TB and cancers. [Updated 2015 May 8; Accessed 2023 March 19] Available from: https://www.who.int/news/item/08-05-2015-who-moves-to-improve-access-to-lifesaving-medicines-for-hepatitis-c-drug-resistant-tb-and-cancers
11. 11.↵
    1. Elsharkawy A,
    2. El-Raziky M,
    3. El-Akel W,
    4. El-Saeed K,
    5. Eletreby R,
    6. Hassany M, et al.

    Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: lessons from the Egyptian experience. J Hepatol 2018; 68: 691–698.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Aljumah AA,
    2. Abaalkhail F,
    3. Al-Ashgar H,
    4. Assiri A,
    5. Babatin M,
    6. Al Faleh F, et al.

    Epidemiology, disease burden, and treatment strategies of chronic hepatitis C virus infections in Saudi Arabia in the new treatment paradigm shift. Saudi J Gastroenterol 2016; 22: 269–281.

    OpenUrl
13. 13.↵
    European Association for the Study of the Liver. Electronic address: [email protected], Clinical Practice Guidelines Panel: Chair:, EASL Governing Board representative, Pawlotsky JM, Negro F, Aghemo A, et al. EASL recommendations on treatment of hepatitis C 2018. J Hepatol 2018; 69: 461–511.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Sulkowski MS,
    2. Gardiner DF,
    3. Rodriguez-Torres M,
    4. Reddy KR,
    5. Hassanein T,
    6. Jacobson I, et al

    ; AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211–221.

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    1. Leroy V,
    2. Angus P,
    3. Bronowicki JP,
    4. Dore GJ,
    5. Hezode C,
    6. Pianko S, et al.

    Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). Hepatology 2016;63: 1430–1441.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Perazzo H,
    2. Castro R,
    3. Luz PM,
    4. Banholi M,
    5. Goldenzon RV,
    6. Cardoso SW, et al.

    Effectiveness of generic direct-acting agents for the treatment of hepatitis C: systematic review and meta-analysis. Bull World Health Organ 2020; 98: 188–197K.

    OpenUrl
17. 17.↵
    1. Al Traif I,
    2. Al Balwi MA,
    3. Abdulkarim I,
    4. Handoo FA,
    5. Alqhamdi HS,
    6. Alotaibi M, et al.

    HCV genotypes among 1013 Saudi nationals: a multicenter study. Ann Saudi Med 2013; 33: 10–12.

    OpenUrl
18. 18.↵
    1. Joharji H,
    2. Alkortas D,
    3. Ajlan A,
    4. Ahmed M,
    5. Al-Ashgar H,
    6. Al-Quaiz M, et al.

    Efficacy of generic sofosbuvir with daclatasvir compared to sofosbuvir/ledipasvir in genotype 4 hepatitis C virus: A prospective comparison with historical control. Health Sci Rep 2022; 6: e980.

    OpenUrl
19. 19.↵
    1. Kjellin M,
    2. Kileng H,
    3. Akaberi D,
    4. Palanisamy N,
    5. Duberg AS,
    6. Danielsson A, et al.

    Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway. Scand J Gastroenterol 2019; 54: 1042–1050.

    OpenUrl
20. 20.↵
    1. Nelson DR,
    2. Cooper JN,
    3. Lalezari JP,
    4. Lawitz E,
    5. Pockros PJ,
    6. Gitlin N, et al

    ; ALLY-3 Study Team. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015 Apr;61(4):1127–35. https://doi.org/10.1002/hep.27726

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Wei L,
    2. Lim SG,
    3. Xie Q,
    4. Văn KN,
    5. Piratvisuth T,
    6. Huang Y, et al.

    Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. Lancet Gastroenterol Hepatol 2019; 4: 127–134.

    OpenUrl
22. 22.↵
    1. Butt N,
    2. Anoshia, Khan MA,
    3. Akbar A

    . Effectiveness of Sofosbuvir and Daclatasvir in treatment of Hepatitis-C: an experience of tertiary care hospital in Karachi. Pak J Med Sci 2021; 37: 2014–2019.

    OpenUrl
23. 23.↵
    1. Mushtaq S,
    2. Mansoor A,
    3. Umar M,
    4. Khan A,
    5. Siddiqi S,
    6. Manzoor S

    . Direct-acting antiviral agents in the treatment of chronic hepatitis C-Real-life experience from clinical practices in Pakistan. J Med Virol 2020; 92: 3475–3487.

    OpenUrl
24. 24.↵
    1. Zeuzem S,
    2. Foster GR,
    3. Wang S,
    4. Asatryan A,
    5. Gane E,
    6. Feld JJ, et al.

    Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med 2018; 378: 354–369.

    OpenUrlCrossRefPubMed
25. 25.
    1. Foster GR,
    2. Afdhal N,
    3. Roberts SK,
    4. Bräu N,
    5. Gane EJ,
    6. Pianko S, et al.

    ASTRAL-2 Investigators; ASTRAL-3 Investigators. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med 2015; 373: 2608–2617.

    OpenUrlCrossRefPubMed
26. 26.
    1. Tasavon Gholamhoseini M,
    2. Sharafi H,
    3. Hl Borba H,
    4. Alavian SM,
    5. Sabermahani A,
    6. Hajarizadeh B

    . Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study. BMJ Open 2022; 12: e058757.

    OpenUrl
27. 27.↵
    1. Soria A,
    2. Fava M,
    3. Bernasconi DP,
    4. Lapadula G,
    5. Colella E,
    6. Valsecchi MG, et al.

    Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort. Liver Int 2020; 40: 769–777.

    OpenUrl
28. 28.↵
    1. He S,
    2. Lockart I,
    3. Alavi M,
    4. Danta M,
    5. Hajarizadeh B,
    6. Dore GJ

    . Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma. Aliment Pharmacol Ther 2020; 51: 34–52.

    OpenUrl
29. 29.↵
    1. Akbar DH,
    2. Siddique AM,
    3. Ahmed MM

    . Prevalence of Type-2 diabetes in patients with hepatitis C and B virus infection in Jeddah, Saudi Arabia. Med Princ Pract 2002; 11: 82–85.

    OpenUrlPubMed
30. 30.↵
    1. Delgado-Borrego A,
    2. Jordan SH,
    3. Negre B,
    4. Healey D,
    5. Lin W,
    6. Kamegaya Y, et al

    ; Halt-C Trial Group. Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol 2010; 8: 458–462.

    OpenUrlCrossRefPubMedWeb of Science
31. 31.↵
    1. Hum J,
    2. Jou JH,
    3. Green PK,
    4. Berry K,
    5. Lundblad J,
    6. Hettinger BD, et al.

    Improvement in glycemic control of type 2 diabetes after successful treatment of hepatitis C virus. Diabetes Care 2017; 40: 1173–1180.

    OpenUrlAbstract/FREE Full Text